Idexx Laboratories (IDXX) Current Deferred Revenue (2009 - 2026)

Idexx Laboratories' Current Deferred Revenue history runs 18 years deep, the most recent figure standing at $36.3 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 3.79% year-over-year to $36.3 million; the TTM figure through Mar 2026 stood at $36.3 million (up 3.79% YoY), while the FY2025 annual figure was $35.3 million, up 4.33% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $36.3 million, up from $35.3 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $40.9 million in Q1 2022, with the low at $33.8 million in Q4 2024.
• The 5-year median for Current Deferred Revenue is $37.8 million (2023), against an average of $37.5 million.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue dropped 9.13% in 2024, then rose 4.33% in 2025.
• Idexx Laboratories' Current Deferred Revenue stood at $37.9 million in 2022, then declined by 1.96% to $37.2 million in 2023, then declined by 9.13% to $33.8 million in 2024, then rose by 4.33% to $35.3 million in 2025, then climbed by 3.02% to $36.3 million in 2026.
• Business Quant data shows IDXX's Current Deferred Revenue at $36.3 million in Q1 2026, $35.3 million in Q4 2025, and $35.7 million in Q3 2025.